Literature DB >> 19889552

Impaired IL-7 signaling may explain a case of atypical JAK3-SCID.

Jun Li1, Hidetoshi Nara, Mizanur Rahman, Farha Matin Juliana, Akemi Araki, Hironobu Asao.   

Abstract

Janus kinase 3-severe combined immunodeficiency (JAK3-SCID) is an autosomal recessive immunodeficiency disease caused by various mutations in the JAK3 gene. Typical JAK3-SCID is characterized by a phenotype in which B cells are present but T and NK cells are not, the T(-)B(+)NK(-) phenotype, and by impaired signaling through cytokine receptors that use the common gamma chain (gammac) subunit. An atypical JAK3-SCID case carrying a single glutamate to glycine substitution mutation (E481G) in the JH3 domain of one JAK3 allele, and a deletion mutation (del482-596) in the JH3 and JH2 domains of the other allele was reported previously. Although this patient had CD4(+) T cells and NK cells unlike typical cases, the CD4(+) T cells were functionally impaired. We report here that the JAK3-E481G mutant transduced IL-2-, IL-4-, IL-15-, and IL-21-induced signals as efficiently as wild-type JAK3. However, this mutant failed to respond to IL-7 by phosphorylating JAK1, JAK3, or STAT5. The other mutant JAK3, JAK3-del482-596, was non-functional. Thus, an impaired IL-7 signal may cause SCID and compromise T-cell differentiation, even if the IL-15 signal is preserved and supports NK-cell development, as in this patient. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889552     DOI: 10.1016/j.cyto.2009.09.009

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  6 in total

1.  IL-8-induced neutrophil chemotaxis is mediated by Janus kinase 3 (JAK3).

Authors:  Karen M Henkels; Kathleen Frondorf; M Elba Gonzalez-Mejia; Andrea L Doseff; Julian Gomez-Cambronero
Journal:  FEBS Lett       Date:  2010-11-21       Impact factor: 4.124

2.  Cell invasion of highly metastatic MTLn3 cancer cells is dependent on phospholipase D2 (PLD2) and Janus kinase 3 (JAK3).

Authors:  Karen M Henkels; Terry Farkaly; Madhu Mahankali; Jeffrey E Segall; Julian Gomez-Cambronero
Journal:  J Mol Biol       Date:  2011-03-22       Impact factor: 5.469

3.  Hypomorphic Janus kinase 3 mutations result in a spectrum of immune defects, including partial maternal T-cell engraftment.

Authors:  Federica Cattaneo; Mike Recher; Stefania Masneri; Sachin N Baxi; Claudia Fiorini; Francesca Antonelli; Christian A Wysocki; Jose G Calderon; Hermann Eibel; Angela R Smith; Francisco A Bonilla; Erdyni Tsitsikov; Silvia Giliani; Luigi D Notarangelo; Sung-Yun Pai
Journal:  J Allergy Clin Immunol       Date:  2013-02-04       Impact factor: 10.793

4.  A case of aberrant CD8 T cell-restricted IL-7 signaling with a Janus kinase 3 defect-associated atypical severe combined immunodeficiency.

Authors:  Aaruni Khanolkar; Jeffrey D Wilks; Guorong Liu; Bridget M Simpson; Edward A Caparelli; Dawn A Kirschmann; Jenna Bergerson; Ramsay L Fuleihan
Journal:  Immunol Res       Date:  2020-02       Impact factor: 2.829

Review 5.  Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival.

Authors:  Michel Morre; Stéphanie Beq
Journal:  Target Oncol       Date:  2012-03-02       Impact factor: 4.493

Review 6.  Chronic active Epstein-Barr virus infection as the initial symptom in a Janus kinase 3 deficiency child: Case report and literature review.

Authors:  Linqing Zhong; Wei Wang; Mingsheng Ma; Lijuan Gou; Xiaoyan Tang; Hongmei Song
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.